<DOC>
	<DOCNO>NCT02743325</DOCNO>
	<brief_summary>Supraventricular tachycardia ablation Conformité Européenne ( CE ) -certified ( since 2013 ) CartoUnivuTM module ( Biosense Webster , Diamond Bar , USA ) allow seamless combination fluoro image Carto® 3 System map single view . This help reduce fluoroscopy level reduce exposure time physician , staff patient low reasonably achievable . The UnivuTM technology compare randomized manner conventional radiofrequency Ablation .</brief_summary>
	<brief_title>As Low As Reasonable Achievable Fluoroscopy SVT Ablation</brief_title>
	<detailed_description>Aim current Randomized Clinical Study assess safety efficiency supraventricular tachycardia ablation CE-certified ( since 2013 ) CartoUnivuTM module ( Biosense Webster , Diamond Bar , USA ) , allow seamless combination fluoro Image Carto® 3 System map single view . It help reduce fluoroscopy level - consistent ALARA principle reduce exposure physician , staff patient low reasonably achievable . The UnivuTM technology compare randomized manner conventional radiofrequency ( RF ) ablation . Patients symptomatic supraventricular tachycardia ( SVT ) include , specifically patient atrioventricular nodal re-entrant tachycardia ( AVRNT ) , atrioventricular re-entrant tachycardia ( AVRT ) typical atrial flutter ( TAF ) . Current ablative treatment consist destroy small area myocardial tissue conduction system , , critical initiation maintenance arrhythmia ( slow pathway Ablation case AVRNT , anomalous extra nodal connection atrium ventricle along atrioventricular groove AVRT cavo-tricuspid isthmus case TAF ) . However , SVT ablation without 3D navigation system certain fluoroscopy time radiation exposure , respectively . Prolonged fluoroscopy radiation exposure ablation may potentially cause increase lifetime risk fatal malignancy . In 1-year follow-up arrhythmia recurrence rate without anti-arrhythmic drug assess use 7-day holter record 60 patient undergoing CartoUnivuTM guide SVT ablation ( group A ) vs. 60 patient undergoing conventional RF-catheter ablation ( without CartoUnivuTM , group B ) . All patient stop anti-arrhythmic drug least 1 week date ablation . Each patient undergo transthoracal echocardiography ( TTE ) intervention . In case transseptal need , heparin administer successful transseptal puncture activate clotting time ( ACT ) -target ≥325 sec . Following data acquire : - Age , gender , presence structural heart disease ( SHD ) , co-morbidities - Duration arrhythmia ( first manifestation long lasting episode ) - Current fail antiarrhythmic therapy - Echocardiography : Dilatation , hypertrophy , regurgitation , Left ventricular ejection fracture ( LVEF ) , important abnormality ( e.g . prolapse ) Ablation SVT : The follow concept use ablation slow pathway ablation case AVRNT , anomalous extra nodal connection atrium ventricle along atrioventricular groove AVRT cavo-tricuspid isthmus case TAF : Using 3D-electro-anatomic system ( CARTO3® ) module fluoroscopy integration ( UnivuTM ) , diagnostic catheter ( 10 pole deflectable catheter fix 4 pole catheter ) introduce without use fluoroscopy registration phase transfer fluoroscopic image anteroposterior ( AP ) leave anterior oblique ( LAO ) projection Carto3® System . Once electrophysiology study realize arrhythmia identify ( activation use purpose ) , ablation catheter ( Navistar® 4mm/8mm , Biosense Webster , Diamond Bar , USA ) introduce ( also without use fluoroscopy ) . In case map do local activation time information , specific tag take : - AVRNT : His , coronary Sinus ( CS ) ostium - AVRT - right atrium : His , CS ostium , tricuspid annulus - left atrium : left inferior vein , appendage , mitral annulus - AF : His , ostium inferior vena cava , tricuspid annulus Aim ablation procedure ablate small area myocardial tissue conduction system , , critical initiation maintenance arrhythmia ( slow pathway ablation case AVRNT , anomalous extra nodal connection atrium ventricle along atrioventricular groove AVRT cavo-tricuspid isthmus case TAF ) use CartoUnivuTM module ( Biosense Webster , Diamond Bar , USA ) fluoroscopy integration Carto 3® System , arrhythmia inducibility . If non-clinical arrhythmia correspond patient symptom induce , pharmacological and/or electrical cardioversion sinus rhythm perform . If coronariography perform , procedure time , fluoroscopy time dos use discount overall respective measurement . Annotation ablation sit 3D-map must perform VisiTag algorithm ( integrate CARTO3® system ) , allow post-procedural analysis catheter stability RF delivery site , duration RF-application value catheter stability ablation . The following procedural data acquire : - Total procedure time ( femoral vein puncture removement sheath ) - Use long sheath ablation catheter ( name type , steerable ) - Duration RF-delivery mean deliver RF-power - Fluoroscopy duration dose - Activation map : yes/no , many point - Complications Follow-up : - Number patient arrhythmia recurrence blanking period ( 3months post 1st ablation procedure stop antiarrhythmic drug ) - 7-day holter rhythm monitor 6 12 month - Phone contact / questionnaire document patient symptoms medication 6 12 month .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Supraventricular</mesh_term>
	<criteria>Patients symptomatic SVT undergo first SVT ablation procedure ( prior history cardiac surgery Structurally normal heart ( major cardiac defect ) Previous ablation SVT ( cardiac surgery ) Contraindications catheter ablation therapy Congenital heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>